Related Experiment Videos
Phenytoin, hemorrhage, skeletal defects and vitamin K in the newborn
Insights
Vitamin K deficiency in newborns can cause bleeding and skeletal issues. Early vitamin K1 administration prevents these risks, especially when mothers take anticonvulsants during pregnancy.
Area of Science:
- Biochemistry
- Neonatal Medicine
- Pharmacology
Background:
- Vitamin K-dependent hemostatic factors are naturally low at birth and can decline further in early infancy.
- Hemorrhagic disease of the newborn is a significant risk associated with low vitamin K levels.
- Maternal anticonvulsant use can exacerbate vitamin K deficiency in newborns.
Purpose of the Study:
- To investigate the link between maternal anticonvulsant use and increased risk of hemorrhage in newborns.
- To elucidate the mechanism by which anticonvulsants may lead to vitamin K deficiency and associated clinical outcomes.
- To highlight the importance of vitamin K1 administration in preventing neonatal hemorrhage.
Main Methods:
- Review of existing evidence on vitamin K metabolism and neonatal hemostasis.
- Analysis of cases where maternal anticonvulsant ingestion correlated with neonatal hemorrhage and skeletal defects.
- Discussion of the role of fetal microsomal enzyme induction in vitamin K degradation.
Main Results:
- Vitamin K1 administration on day 1 effectively prevents hemorrhagic disease of the newborn.
- Maternal anticonvulsants may induce fetal enzymes, increasing vitamin K oxidative degradation.
- This process leads to vitamin K deficiency, increasing hemorrhage and skeletal defect risks in newborns.
Conclusions:
- Vitamin K deficiency poses significant risks to newborns, including hemorrhage and skeletal abnormalities.
- Prophylactic vitamin K1 is crucial for preventing neonatal bleeding disorders.
- Understanding the impact of maternal medication on fetal vitamin K status is vital for preventing adverse outcomes.
Abstract:
The vitamin K-dependent hemostatic factors are present in reduced quantities at birth and may decrease further in the first few days of life. Administration of vitamin K1 on day 1 prevents hemorrhagic disease of the newborn. Maternal ingestion of anticonvulsants puts the newborn at greater risk from hemorrhage, possibly as a result of induction of fetal microsomal enzymes with a resultant increased oxidative degradation of vitamin K which gives rise to a vitamin K deficiency and other concomitant clinical results, for example skeletal defects. Evidence for this sequence of events is presented and the widespread effect of vitamin K deficiency on the fetus is discussed.